Learning Objectives
Upon completion of this activity, participants should be able to:
- Apply recent clinical trial results in the treatment of patients with advanced ovarian cancer
- Discuss phase II and phase III data from clinical trials of monotherapies and combination regimens for the treatment of ovarian cancer
- Compare investigational chemotherapy regimens with standard chemotherapy for frontline treatment of ovarian cancer
- Cite novel approaches and emerging agents with promise in the management of platinum-sensitive and platinum-resistant ovarian cancer
- Describe advances in the development of a screening strategy for ovarian cancer
- Provide appropriate care & counsel for patients and their families
Topics covered include:
- Bevacizumab-based First-line Regimen and Maintenance Therapy for Advanced Ovarian Cancer
- First-line Gemcitabine/Carboplatin vs Paclitaxel/Carboplatin, Followed by Paclitaxel Maintenance for Advanced Epithelial Ovarian Cancer
- Frontline PLD/Carboplatin vs Paclitaxel/Carboplatin for Advanced Ovarian Cancer
- Exploration of PARP Inhibitors in Ovarian Cancer With and Without BRCA Mutations
- New Antiangiogenesis Inhibitor for the Treatment of Recurrent Ovarian Cancer: AMG 386
- Novel Monoclonal Antibody for the Treatment of Platinum-sensitive Epithelial Ovarian Cancer: Farletuzumab
- Novel Vincristine-based Agent for the Treatment of Platinum-resistant Advanced Ovarian Cancer: EC125
- Nab-Paclitaxel Plus Bevacizumab in Platinum-resistant Primary Epithelial Ovarian Cancer or Primary Peritoneal Cancer
- Novel Irinotecan-based Agent for the Treatment of Platinum-resistant/refractory Ovarian Cancer: NKTR-102
- Platinum-free Interval Extension With Trabectedin/PLD in Partially Platinum-sensitive Recurrent Ovarian Cancer
- 2-Step Screening Strategy for Ovarian Cancer Using Annual CA-125 Measurement and Possible Transvaginal Ultrasound
Abstract